Aug 2026· Japanese Journal of Clinical Oncology· 0 citations
Medicine
TL;DR
Current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes are summarized and integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches.
HER2-positive early breast cancer (EBC) accounts for 15–20% of breast cancer cases and is characterized by aggressive biology, though outcomes have significantly improved with HER2-directed therapies. This narrative review summarizes contemporary approaches to personalize systemic treatment of HER2-positive EBC through...
C. O'Sullivan· Therapeutic Advances in Medi...· 0 citations
Hormone receptor–positive (HR+) breast cancer is the most common subtype of the disease and is characterized by significant heterogeneity in its clinical course and response to therapy. Adjuvant endocrine therapy with aromatase inhibitors represents a highly effective alternative to chemotherapy in postmenopausal patie...
M. Dzhelialova, A. V. Zolotukhina, A. Shalaev et al.· Medical alphabet· 0 citations
Adjuvant treatment of colorectal cancer (CRC) has traditionally been based on fluoropyrimidine- and oxaliplatin-based chemotherapy regimens, which remain the cornerstone of care for patients with resected stage III and selected high-risk stage II disease. However, despite substantial improvements in disease-free (DFS...
G. Piringer· memo - Magazine of European...· 0 citations
Muscle-invasive bladder cancer (MIBC) remains associated with high recurrence and mortality despite radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC). For decades, perioperative therapy was defined by platinum-based regimens, which improve survival but are limited to fewer than half of patients due...
Cheyenne Williams, Yash B. Shah, Lei-Lei Xia· Therapeutic Advances in Urol...· 0 citations
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety an...
Emily P. Rabinovich, Linda W. Martin· Journal of Clinical Medicine· 0 citations
BACKGROUND
The prognosis of metastatic nasopharyngeal carcinoma (mNPC) remains dismal despite recent advances of locoregional and systemic therapy. The incorporation of programmed death-1 (PD-1) inhibitors into first-line chemotherapy has transformed the therapeutic landscape; however, optimal treatment strategies beyo...
Wei-Jie Wen, Ji-Shi Li, Yuan-Mei Qu et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.